Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Renal Function Clinical Trial

Official title:

A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02634437
• Other study ID #: UPA-PK-02
• Status: Completed
• Phase: Phase 1
• First received: December 16, 2015
• Last updated: February 6, 2018
• Start date: December 1, 2015
• Est. completion date: December 9, 2016

Study information

• Verified date: February 2018
• Source: Allergan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: December 9, 2016
• Est. primary completion date: December 9, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria for Patients with Renal Impairment:

• Have a negative result from a serum pregnancy test at screening and a negative result from a serum or urine pregnancy test on Day -1

• If premenopausal, have regular menstrual cycles (cycles of 24-35 days duration) over the past 6 months as reported by the patient

• If female of childbearing potential, agree to use an effective method of contraception (i.e., condom plus diaphragm with spermicide, condom with spermicide, or nonhormonal intrauterine device) and not become pregnant throughout the study. Subjects who are at least 2-years postmenopausal (with supporting documentation from an obstetrician/gynecologist) or who have had tubal ligation or hysterectomy will not be considered to be of childbearing potential

• Be nonsmoking (never smoked or have not smoked within the previous 6 months) or a light smoker (fewer than 10 cigarettes per day within the previous 3 months)

• For Patients with Renal Impairment, have medical history, physical examination, laboratory, and other test results consistent with their degree of renal impairment, as determined by the Investigator

• For Patients with Normal Renal Function, have a state of general good health based on medical history and routine physical examination and are matched to the age and weight of the renal dysfunction patients (mean group difference ±10 years for age and < 20% for weight)

Exclusion Criteria:

• Known hypersensitivity to Ulipristal Acetate (UPA) or other selective progesterone receptor modulators

• For Patients with Renal Impairment, clinically significant disease state, in the opinion of the examining physician, in any body system (other than renal function impairment)

• For Patients with Normal Renal Function, clinically significant disease state, in the opinion of the examining physician, in any body system

• Positive test results for anti-human immunodeficiency virus type 1, hepatitis B surface antigen, or anti-hepatitis C virus at screening

• Abnormal and clinically significant results on physical examination, medical history, serum chemistry, hematology, or urinalysis

• History of alcohol or other substance abuse within the previous 5 years

• Positive test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at screening or Day -1. Patients with Renal Impairment many be enrolled if the positive test result is due to prescription drug use and approved by the Principal Investigator and Sponsor Study Physician, on a case-by-case basis

• Participation in any other clinical investigation using an experimental drug requiring repeated blood or plasma draws within 30 days of IP administration

• Participation in a blood or plasma donation program within 60 or 30 days, respectively, of Investigational Product (IP) administration

• Previously participated in an investigational study of Ulipristal Acetate

• Breastfeeding

Related Conditions & MeSH terms

• Renal Function
• Renal Insufficiency

Intervention

Drug:
• Ulipristal acetate

Locations

Country	Name	City	State
United States	Clinical Pharmacology of Miami	Miami	Florida
United States	Division of Clinical Pharmacology, University of Miami	Miami	Florida
United States	Orlando Clinical Research Center	Orlando	Florida
United States	Prism Clinical Research	Saint Paul	Minnesota
United States	QPS Bio-Kinetic	Springfield	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to time t (AUC 0-t)		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Maximum plasma drug concentration (Cmax) of ulipristal acetate		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Time of maximum plasma drug concentration (Tmax) of ulipristal acetate		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Terminal elimination half-life (T½) of ulipristal acetate		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Apparent total body clearance of ulipristal acetate from plasma after extravascular administration (CL/F) of ulipristal acetate		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of ulipristal acetate		Day 1 (0 hour) to Day 8 (168 hours)
Primary	Area under the plasma concentration versus time curve of ulipristal acetate from time 0 to infinity (AUC 0-8)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to time t (AUC 0-t)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Time of maximum plasma drug concentration (Tmax) of PGL4002 (ulipristal acetate active metabolite)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Terminal elimination half-life (T½) of PGL4002 (ulipristal acetate active metabolite)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Maximum plasma drug concentration (Cmax) of PGL4002 (ulipristal acetate active metabolite)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Cumulative amount of ulipristal acetate excreted into urine from time zero to time t (Ae0-t)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Renal clearance of ulipristal acetate from plasma (CLR)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Percent of dose excreted as unchanged ulipristal acetate in urine (%Dose)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Cumulative amount of PGL4002 excreted into urine from time zero to time t (Ae0-t)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Renal clearance of PGL4002 from plasma (CLR)		Day 1 (0 hour) to Day 8 (168 hours)
Secondary	Area under the plasma concentration versus time curve of PGL4002 (ulipristal acetate active metabolite) from time 0 to infinity (AUC 0-8)		Day 1 (0 hour) to Day 8 (168 hours)